- PAT (Standalone) include INR 332.94 Mn, Dividend from Suven Pharma, Inc., USA.
- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- The consolidated financials include the results of the wholly owned subsidiary Suven Pharma, Inc., and associate Rising Pharma Holdings, Inc., USA.
- The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.
- Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non availability of materials with increase in materials cost are impacting our operations and profitability.